BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA

Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C...

Full description

Saved in:
Bibliographic Details
Main Authors AHMADI, Tahamtan, ELLIOT, Brian
Format Patent
LanguageEnglish
French
Published 17.03.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin). L'invention concerne des méthodes de traitement clinique de lymphome diffus à grandes cellules B (DLBCL) (par exemple, d'un DLBCL de rechute et/ou réfractaire éligible à une greffe de cellules souches autologues) chez des sujets humains à l'aide d'un anticorps bispécifique qui se lie à CD3 et à CD20 en combinaison avec un standard de régime de soins de R-DHAX/C (Rituximab, Dexaméthasone, Cytarabine, et Oxaliplatine/Carboplatine).
Bibliography:Application Number: WO2021EP75021